DFFN News and Press, Diffusion Pharmaceuticals Inc. From 08/12/22

Diffusion Pharmaceuticals press release ( NASDAQ: DFFN ): Q2 GAAP EPS of -$2.06 misses by $0.02 . As of June 30, 2022, Diffusion had $28.5M in cash, cash equivalents, and marketable securities, which the company currently expects will enable it to fund its operati...

•  Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022 •  Reported Positive Effects in TSC Altitude Trial •  Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Sec...

Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”) patients Company to evaluate effects of TSC on tumor oxygenation ...

Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval Positive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise interval TSC was safe and well-t...

CHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the body’s ability to deliver oxygen to areas where i...

CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas w...

Diffusion Pharmaceuticals press release (NASDAQ:DFFN): Q1 GAAP EPS of -$2.22. As of March 31, 2022, Diffusion reported $32.6 million in cash, cash equivalents, and marketable securities, which is expected to fund the Company’s operating expenses and capital expenditure requirements thr...

Completed Dosing in Altitude Trial; Topline Data Expected in June 2022 Blinded, Interim Data to be Presented at UHMS Annual Scientific Meeting in May 2022 Ended Quarter with $32.6 Million in Cash, Cash Equivalents and Marketable Securities Regained Compliance with Nasdaq Bid...

Nasdaq Listing Qualifications Staff notified Diffusion Pharmaceuticals (NASDAQ:DFFN) that it has regained compliance with the Nasdaq minimum bid price continued listing requirement. Earlier, it was notified on May 6 that it is not in compliance with the minimum bid price requirement. For fu...

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas w...